On October 22, 2020 BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) reported that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant (GARP) directed antibody (Press release, BioInvent, OCT 22, 2020, https://www.prnewswire.com/news-releases/bioinvent-receives-2-million-milestone-from-daiichi-sankyo-301157650.html [SID1234568754]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first-in-human, global, multi-center, open-label phase l dose escalation study, being conducted by Daiichi Sankyo, will evaluate the safety and tolerability of DS-1055 in adult patients with advanced or metastatic solid tumors.
The antibody DS-1055 was discovered by Daiichi Sankyo and targets GARP, a transmembrane protein expressed on the surface of regulatory T cells (Tregs), which are involved in immune tolerance and have strong immunosuppressive activity.i
The discovery of DS-1055 was supported by access to BioInvent’s proprietary n-CoDeR antibody library through a collaboration agreement. Under the terms of the agreement, payments are due to BioInvent when certain clinical milestones are achieved, and royalty payments are due on net sales when a product is commercialized.
Martin Welschof, CEO of BioInvent, said: "We are very pleased with the initiation of this Phase I clinical trial with DS-1055 and look forward to further collaboration with Daiichi Sankyo. We continue to apply our versatile n-CoDeR/F.I.R.S.T technology platform to our in-house clinical development program, and to our partnering model which gives us many shots on goal."